Go-ahead for LCT
Tuesday, 21 October, 2008
Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.
NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.
A parallel Phase I/IIa trial commenced in Russia in 2007.
According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.
DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
